Erratum: Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: A randomized clinical trial (JAMA (2018) 320:6 (566-579) DOI: 10.1001/jama.2018.10359);Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 320, Issue 6, 2018, Pages 566-579

  Webster, Ruth ^a   Salam, Abdul ^a   De Silva, H Asita ^b   Selak, Vanessa ^c   Stepien, Sandrine ^a   Rajapakse, Senaka ^d   Amarasekara, Stanley ^e   Amarasena, Naomali ^f   Billot, Laurent ^a   De Silva, Arjuna P ^b   Fernando, Mervyn ^e   Guggilla, Rama ^g   Jan, Stephen ^a   Jayawardena, Jayanthimala ^e   Maulik, Pallab K ^a   Mendis, Sepalika ^e   Mendis, Suresh ^h   Munasinghe, Janake ^e   Naik, Nitish ⁱ   Prabhakaran, Dorairaj ^j   Ranasinghe, Gotabaya ^e   Thom, Simon ^k   Tisserra, Nirmali ^e   Senaratne, Vajira ^e   Wijekoon, Sanjeewa ^l   Wijeyasingam, Santharaj ^e   Rodgers, Anthony ^a   Patel, Anushka ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF KELANIYA   (Sri Lanka)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF COLOMBO   (Sri Lanka)

^e NATIONAL HOSPITAL OF SRI LANKA   (Sri Lanka)

^f Sri Jayawardenapura General Hospital   (Sri Lanka)

^g MINISTRY OF HEALTH   (Saudi Arabia)

^h Department of Anaesthesiology College of Anaesthesiologists and Intensivists of Sri Lanka   (Sri Lanka)

ⁱ ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^j CENTRE FOR CHRONIC DISEASE CONTROL   (India)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF SRI JAYEWARDENEPURA   (Sri Lanka)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS CHLORTHALIDONE PLUS TELMISARTAN; ANTIHYPERTENSIVE AGENT; UNCLASSIFIED DRUG; AMLODIPINE; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID; CHLORTALIDONE; POTASSIUM; TELMISARTAN;

ADULT; ANGINA PECTORIS; APPLICATION SITE REACTION; ARTICLE; BENIGN NEOPLASM; BLOOD PRESSURE REGULATION; BREAST DISEASE; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG SAFETY; EAR DISEASE; ENDOCRINE DISEASE; FAINTNESS; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; HYPESTHESIA; HYPOTENSION; IMMUNOPATHOLOGY; INFECTION; INJURY; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDIASTINUM DISEASE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PERIPHERAL EDEMA; PRESYNCOPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; SRI LANKA; SYSTOLIC BLOOD PRESSURE; THORAX DISEASE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; VASCULAR DISEASE; AGED; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; MEDICATION COMPLIANCE; MIDDLE AGED;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POTASSIUM; SRI LANKA;

EID: 85051632970     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.17363     Document Type: Erratum

References (39)

1. Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016. Lancet. 2017;390(10100):1345-1422.
2. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events. Lancet. 2003;362(9395): 1527-1535. doi:10.1016/S0140-6736(03)14739-3
3. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control. Circulation. 2016;134(6):441-450.
4. Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries. Lancet. 2016;387(10013):61-69.
5. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs. BMJ. 2003;326(7404): 1427-1431. doi:10.1136/bmj.326.7404.1427
6. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569-588.
7. Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and management of hypertension in adults-2016. Med J Aust. 2016;205 (2):85-89. doi:10.5694/mja16.00526
8. Whelton PK, Carey RM, AronowWS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults [published correction appears in J AmColl Cardiol.2018;71(19):2275-2279]. J AmColl Cardiol. 2018;71(19):e127-e248.
9. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7(7):e41297.
10. Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension. Lancet. 2017;389 (10073):1035-1042.
11. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension. 2010;55(2):399-407.
12. Webster R, Patel A, Selak V, et al. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk. Int J Cardiol. 2016;205:147-156. doi:10.1016/j.ijcard.2015.12.015
13. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345-351.
14. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic. J Clin Hypertens (Greenwich). 2013;15(3):193-200.
15. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454-463. doi:10.1056/NEJMra1510059
16. Salam A, Webster R, Singh K, et al. TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH). Am Heart J. 2014;167(2):127-132.
17. Webster R. Protocol changes to the TRIUMPH study. Am Heart J. 2017; 191: E1.
18. EuroQol Group. EuroQol - A new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
19. Bennett A, Chow CK, Chou M, et al. Efficacy and safety of quarter-dose blood pressure-lowering agents. Hypertension. 2017;70(1):85-93.
20. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension. Hypertension. 2009; 53(4):646-653.
21. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide. Hypertension. 2009;54(1):32-39.
22. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3): 219-242. doi:10.1177/0962280206074463
23. Abdi H. Holm's sequential Bonferroni procedure. In: Encyclopedia of Research Design. Thousand Oaks, CA: SAGE Publications; 2010:1-8.
24. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure. Am J Med. 2009;122(3): 290-300. doi:10.1016/j.amjmed.2008.09.038
25. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination. Hypertension. 2007; 49(2):272-275.
26. MacDonald TM, Williams B, Webb DJ, et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension. J AmHeart Assoc. 2017;6(11):6.
27. Mourad JJ, Waeber B, Zannad F, et al. Comparison of different therapeutic strategies in hypertension. J Hypertens. 2004;22(12):2379-2386.
28. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control inWestern Europe and the United States. Arch Intern Med. 2007;167(2): 141-147. doi:10.1001/archinte.167.2.141
29. Ferrari P; National Coordinators for the Reasons for not Intensifying Antihypertensive Treatment (RIAT) trial12. Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. J Hum Hypertens. 2009;23(3):151-159. doi:10.1038/jhh.2008.117
30. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011; 124(9):1046-1058.
31. Redon J, Coca A, Lazaro P, et al. Factors associated with therapeutic inertia in hypertension. J Hypertens. 2010;28(8):1770-1777.
32. Katulanda P, Ranasinghe P, Jayawardena R, et al. The prevalence, predictors and associations of hypertension in Sri Lanka. Clin Exp Hypertens. 2014;36(7):484-491.
33. Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management?. Int J Cardiol. 2018;254:328-332.
34. Goldman AI, Steele BW, Schnaper HW, et al. Serum lipoprotein levels during chlorthalidone therapy. JAMA. 1980;244(15):1691-1695.
35. Olde Engberink RH, FrenkelWJ, van den Bogaard B, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality. Hypertension. 2015;65(5):1033-1040.
36. Beddhu S, Rocco MV, Toto R, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease. Ann Intern Med. 2017;167(6):375-383.
37. AttaeiMW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries. Lancet Public Health. 2017;2(9):e411-e419.
38. Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018;137(2): 109-118.
39. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013; 310(7):699-705. doi:10.1001/jama.2013.108769